These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
165 related articles for article (PubMed ID: 16648862)
1. Expression profiling of transcription factors Pax-5, Oct-1, Oct-2, BOB.1, and PU.1 in Hodgkin's and non-Hodgkin's lymphomas: a comparative study using high throughput tissue microarrays. McCune RC; Syrbu SI; Vasef MA Mod Pathol; 2006 Jul; 19(7):1010-8. PubMed ID: 16648862 [TBL] [Abstract][Full Text] [Related]
2. Analysis of transcription factor OCT.1, OCT.2 and BOB.1 expression using tissue arrays in classical Hodgkin's lymphoma. García-Cosío M; Santón A; Martín P; Camarasa N; Montalbán C; García JF; Bellas C Mod Pathol; 2004 Dec; 17(12):1531-8. PubMed ID: 15257313 [TBL] [Abstract][Full Text] [Related]
3. Analysis of octamer-binding transcription factors Oct2 and Oct1 and their coactivator BOB.1/OBF.1 in lymphomas. Sáez AI; Artiga MJ; Sánchez-Beato M; Sánchez-Verde L; García JF; Camacho FI; Franco R; Piris MA Mod Pathol; 2002 Mar; 15(3):211-20. PubMed ID: 11904338 [TBL] [Abstract][Full Text] [Related]
4. B-cell transcription factors Pax-5, Oct-2, BOB.1, Bcl-6, and MUM1 are useful markers for the diagnosis of nodular lymphocyte predominant Hodgkin lymphoma. Herbeck R; Teodorescu Brînzeu D; Giubelan M; Lazăr E; Dema A; Ioniţă H Rom J Morphol Embryol; 2011; 52(1):69-74. PubMed ID: 21424034 [TBL] [Abstract][Full Text] [Related]
6. The transcription factor PU.1, necessary for B-cell development is expressed in lymphocyte predominance, but not classical Hodgkin's disease. Torlakovic E; Tierens A; Dang HD; Delabie J Am J Pathol; 2001 Nov; 159(5):1807-14. PubMed ID: 11696441 [TBL] [Abstract][Full Text] [Related]
7. Clusterin expression in malignant lymphomas: a survey of 266 cases. Saffer H; Wahed A; Rassidakis GZ; Medeiros LJ Mod Pathol; 2002 Nov; 15(11):1221-6. PubMed ID: 12429802 [TBL] [Abstract][Full Text] [Related]
8. Use of an expanded immunohistochemical panel to distinguish cutaneous Hodgkin lymphoma from histopathologic imitators. Cho RJ; McCalmont TH; Ai WZ; Fox LP; Treseler P; Pincus LB J Cutan Pathol; 2012 Jun; 39(6):651-8. PubMed ID: 22324490 [TBL] [Abstract][Full Text] [Related]
9. Leukocyte-specific phosphoprotein-1 and PU.1: two useful markers for distinguishing T-cell-rich B-cell lymphoma from lymphocyte-predominant Hodgkin's disease. Marafioti T; Mancini C; Ascani S; Sabattini E; Zinzani PL; Pozzobon M; Pulford K; Falini B; Jaffe ES; Müller-Hermelink HK; Mason DY; Pileri SA Haematologica; 2004 Aug; 89(8):957-64. PubMed ID: 15339679 [TBL] [Abstract][Full Text] [Related]
10. J chain and myocyte enhancer factor 2B are useful in differentiating classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Moore EM; Swerdlow SH; Gibson SE Hum Pathol; 2017 Oct; 68():47-53. PubMed ID: 28851661 [TBL] [Abstract][Full Text] [Related]
11. Disruption of the B-cell specific transcriptional program in HHV-8 associated primary effusion lymphoma cell lines. Arguello M; Sgarbanti M; Hernandez E; Mamane Y; Sharma S; Servant M; Lin R; Hiscott J Oncogene; 2003 Feb; 22(7):964-73. PubMed ID: 12592383 [TBL] [Abstract][Full Text] [Related]
12. The B-cell transcription factors BSAP, Oct-2, and BOB.1 and the pan-B-cell markers CD20, CD22, and CD79a are useful in the differential diagnosis of classic Hodgkin lymphoma. Browne P; Petrosyan K; Hernandez A; Chan JA Am J Clin Pathol; 2003 Nov; 120(5):767-77. PubMed ID: 14608905 [TBL] [Abstract][Full Text] [Related]
13. Transcription factor B-cell-specific activator protein (BSAP) is differentially expressed in B cells and in subsets of B-cell lymphomas. Krenacs L; Himmelmann AW; Quintanilla-Martinez L; Fest T; Riva A; Wellmann A; Bagdi E; Kehrl JH; Jaffe ES; Raffeld M Blood; 1998 Aug; 92(4):1308-16. PubMed ID: 9694719 [TBL] [Abstract][Full Text] [Related]
14. Expression of immunoglobulin transcription factors in primary intraocular lymphoma and primary central nervous system lymphoma. Coupland SE; Loddenkemper C; Smith JR; Braziel RM; Charlotte F; Anagnostopoulos I; Stein H Invest Ophthalmol Vis Sci; 2005 Nov; 46(11):3957-64. PubMed ID: 16249468 [TBL] [Abstract][Full Text] [Related]
15. Differential Emu enhancer activity and expression of BOB.1/OBF.1, Oct2, PU.1, and immunoglobulin in reactive B-cell populations, B-cell non-Hodgkin lymphomas, and Hodgkin lymphomas. Loddenkemper C; Anagnostopoulos I; Hummel M; Jöhrens-Leder K; Foss HD; Jundt F; Wirth T; Dörken B; Stein H J Pathol; 2004 Jan; 202(1):60-9. PubMed ID: 14694522 [TBL] [Abstract][Full Text] [Related]
16. High expression of the CC chemokine TARC in Reed-Sternberg cells. A possible explanation for the characteristic T-cell infiltratein Hodgkin's lymphoma. van den Berg A; Visser L; Poppema S Am J Pathol; 1999 Jun; 154(6):1685-91. PubMed ID: 10362793 [TBL] [Abstract][Full Text] [Related]
17. Dendritic reticulum cell immunoreactivity for low-affinity nerve growth factor receptor in malignant lymphomas. Dorfman DM; Shahsafaei A Mod Pathol; 1996 Oct; 9(10):959-65. PubMed ID: 8902831 [TBL] [Abstract][Full Text] [Related]
18. Expression of CD95 antigen and Bcl-2 protein in non-Hodgkin's lymphomas and Hodgkin's disease. Nguyen PL; Harris NL; Ritz J; Robertson MJ Am J Pathol; 1996 Mar; 148(3):847-53. PubMed ID: 8774139 [TBL] [Abstract][Full Text] [Related]
19. The FOXP1 transcription factor is expressed in the majority of follicular lymphomas but is rarely expressed in classical and lymphocyte predominant Hodgkin's lymphoma. Brown P; Marafioti T; Kusec R; Banham AH J Mol Histol; 2005 May; 36(4):249-56. PubMed ID: 16200457 [TBL] [Abstract][Full Text] [Related]
20. Oct-2 and Bob-1 deficiency in Hodgkin and Reed Sternberg cells. Re D; Müschen M; Ahmadi T; Wickenhauser C; Staratschek-Jox A; Holtick U; Diehl V; Wolf J Cancer Res; 2001 Mar; 61(5):2080-4. PubMed ID: 11280769 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]